References
- Masoli M, Fabian D, Holt S, et al. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78
- Masoli M, Fabian D, Holt S, et al. Global burden of asthma. Report developed for the Global Initiative for Asthma, 2004. [Available at http://www.ginasthma.org. Accessed: 16 October 2007]
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH publication 02-3659 issued January 1995 (updated November 2007. [Available at: www.ginasthma.com. Accessed on: 1 December 2007]
- Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10:2441-2
- van Noord JA, Smeets JJ, Raaijmakers JA, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996;9:1684-8
- Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem?. Ann Allergy Asthma Immunol 1997;79:177-85
- van Schayck CP, Bijl-Hofland ID, Folgering H, et al. Influence of two different inhalation devices on therapy compliance in asthmatic patients. Scand J Prim Health Care 2002;20:126-8
- Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 2007;81:108-13
- US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. E14 Clinical evaluation of QT/QTc interval prolongation and proarhythmic potential for non-antiarrhythmic drugs. October 2005. Available at: http://www.fda.gov/cder/guidance/index.htm
- Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68
- Kanniess F, Boulet L-P, Pierzchala W, et al. Efficacy and safety of indacaterol, a novel 24-h β2-agonist, in patients with asthma: a dose-ranging study. J Asthma 2008;45:887-92
- Beeh KM, Derom E, Kanniess F, et al. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007;29:871-8
- LaForce C, Alexander M, Deckelmann R, et al. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy 2008;63:103-11
- Pearlman DS, Greos L, LaForce C, et al. Bronchodilator efficacy of indacaterol, a novel once-daily β2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol 2008;101:90-95
- Pascoe S, Reynolds C, Pleskow W, et al. Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma. Eur Respir J 2007;30(Suppl 51):350s (P2115)
- Chuchalin AG, Tsoi AN, Richter K, et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 2007;101:2065-75
- Yang WH, Martinot JB, Pohunek P, et al. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann Allergy Asthma Immunol 2007;99:555-61